SYDNEY Australia 16 April 2020– Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Australian rapid blood test company Atomo Diagnostics Limited (Atomo) will commence on the Australian Securities Exchange (ASX) today under the ticker code...

Atomo Diagnostics announced today that it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s integrated blood test devices to NG Biotech to use for its blood-based rapid test to detect COVID-19. Under the...